Top

Published in:

Open Access 01-12-2017 | Minireview

The genetics of gout: towards personalised medicine?

Authors: Nicola Dalbeth, Lisa K. Stamp, Tony R. Merriman

Published in: BMC Medicine | Issue 1/2017

Abstract

Over the last decade, there have been major advances in the understanding of the genetic basis of hyperuricaemia and gout as well as of the pharmacogenetics of urate-lowering therapy. Key findings include the reporting of 28 urate-associated loci, the discovery that ABCG2 plays a central role on extra-renal uric acid excretion, the identification of genes associated with development of gout in the context of hyperuricaemia, recognition that ABCG2 variants influence allopurinol response, and the impact of HLA-B*5801 testing in reducing the prevalence of allopurinol hypersensitivity in high-risk populations. These advances, together with the reducing cost of whole genome sequencing, mean that integrated personalised medicine approaches may soon be possible in clinical practice. Genetic data may inform assessment of disease prognosis in individuals with hyperuricaemia or established gout, personalised lifestyle advice, selection and dosing of urate-lowering therapy, and prevention of serious medication adverse effects. In this article, we summarise the discoveries from genome-wide association studies and discuss the potential for translation of these findings into clinical practice.

Kalousdian S, Fabsitz R, Havlik R, Christian J, Rosenman R. Heritability of clinical chemistries in an older twin cohort: the NHLBI Twin Study. Genet Epidemiol. 1987;4(1):1–11.CrossRefPubMed

Krishnan E, Lessov-Schlaggar CN, Krasnow RE, Swan GE. Nature versus nurture in gout: a twin study. Am J Med. 2012;125(5):499–504.CrossRefPubMed

Whitfield JB, Martin NG. Inheritance and alcohol as factors influencing plasma uric acid levels. Acta Genet Med Gemellol (Roma). 1983;32(2):117–26.CrossRef

Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, Reynolds AP, Sandstrom R, Qu H, Brody J, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science. 2012;337(6099):1190–5.CrossRefPubMedPubMedCentral

Kottgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, Pistis G, Ruggiero D, O'Seaghdha CM, Haller T, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 2013;45(2):145–54.CrossRefPubMed

Li S, Sanna S, Maschio A, Busonero F, Usala G, Mulas A, Lai S, Dei M, Orru M, Albai G, et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet. 2007;3(11), e194.CrossRefPubMedPubMedCentral

Doring A, Gieger C, Mehta D, Gohlke H, Prokisch H, Coassin S, Fischer G, Henke K, Klopp N, Kronenberg F, et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet. 2008;40(4):430–6.CrossRefPubMed

Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott SA, Kolcic I, Polasek O, Graessler J, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet. 2008;40(4):437–42.CrossRefPubMed

Dehghan A, Kottgen A, Yang Q, Hwang SJ, Kao WL, Rivadeneira F, Boerwinkle E, Levy D, Hofman A, Astor BC, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet. 2008;372(9654):1953–61.CrossRefPubMedPubMedCentral

10.

Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, Mangino M, Albrecht E, Wallace C, Farrall M, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 2009;5(6), e1000504.CrossRefPubMedPubMedCentral

11.

Yang Q, Kottgen A, Dehghan A, Smith AV, Glazer NL, Chen MH, Chasman DI, Aspelund T, Eiriksdottir G, Harris TB, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet. 2010;3(6):523–30.CrossRefPubMedPubMedCentral

12.

Okada Y, Sim X, Go MJ, Wu JY, Gu D, Takeuchi F, Takahashi A, Maeda S, Tsunoda T, Chen P, et al. Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations. Nat Genet. 2012;44(8):904–9.CrossRefPubMedPubMedCentral

13.

Charles BA, Shriner D, Doumatey A, Chen G, Zhou J, Huang H, Herbert A, Gerry NP, Christman MF, Adeyemo A, et al. A genome-wide association study of serum uric acid in African Americans. BMC Med Genomics. 2011;4:17.CrossRefPubMedPubMedCentral

14.

Tin A, Woodward OM, Kao WH, Liu CT, Lu X, Nalls MA, Shriner D, Semmo M, Akylbekova EL, Wyatt SB, et al. Genome-wide association study for serum urate concentrations and gout among African Americans identifies genomic risk loci and a novel URAT1 loss-of-function allele. Hum Mol Genet. 2011;20(20):4056–68.CrossRefPubMedPubMedCentral

15.

Kenny EE, Kim M, Gusev A, Lowe JK, Salit J, Smith JG, Kovvali S, Kang HM, Newton-Cheh C, Daly MJ, et al. Increased power of mixed models facilitates association mapping of 10 loci for metabolic traits in an isolated population. Hum Mol Genet. 2011;20(4):827–39.CrossRefPubMed

16.

Voruganti VS, Kent Jr JW, Debnath S, Cole SA, Haack K, Goring HH, Carless MA, Curran JE, Johnson MP, Almasy L, et al. Genome-wide association analysis confirms and extends the association of SLC2A9 with serum uric acid levels to Mexican Americans. Front Genet. 2013;4:279.CrossRefPubMedPubMedCentral

17.

Phipps-Green AJ, Merriman ME, Topless R, Altaf S, Montgomery GW, Franklin C, Jones GT, van Rij AM, White D, Stamp LK, et al. Twenty-eight loci that influence serum urate levels: analysis of association with gout. Ann Rheum Dis. 2016;75(1):124–30.CrossRefPubMed

18.

Urano W, Taniguchi A, Inoue E, Sekita C, Ichikawa N, Koseki Y, Kamatani N, Yamanaka H. Effect of genetic polymorphisms on development of gout. J Rheumatol. 2013;40(8):1374–8.CrossRefPubMed

19.

Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, Lango Allen H, Lindgren CM, Luan J, Magi R, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42(11):937–48.CrossRefPubMedPubMedCentral

20.

Kimura T, Takahashi M, Yan K, Sakurai H. Expression of SLC2A9 isoforms in the kidney and their localization in polarized epithelial cells. PLoS One. 2014;9(1), e84996.CrossRefPubMedPubMedCentral

21.

Hurba O, Mancikova A, Krylov V, Pavlikova M, Pavelka K, Stiburkova B. Complex analysis of urate transporters SLC2A9, SLC22A12 and functional characterization of non-synonymous allelic variants of GLUT9 in the Czech population: no evidence of effect on hyperuricemia and gout. PLoS One. 2014;9(9), e107902.CrossRefPubMedPubMedCentral

22.

Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. 2009;106(25):10338–42.CrossRefPubMedPubMedCentral

23.

Huls M, Brown CD, Windass AS, Sayer R, van den Heuvel JJ, Heemskerk S, Russel FG, Masereeuw R. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int. 2008;73(2):220–5.CrossRefPubMed

24.

Matsuo H, Takada T, Ichida K, Nakamura T, Nakayama A, Ikebuchi Y, Ito K, Kusanagi Y, Chiba T, Tadokoro S, et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med. 2009;1(5):5ra11.CrossRefPubMed

25.

Ichida K, Matsuo H, Takada T, Nakayama A, Murakami K, Shimizu T, Yamanashi Y, Kasuga H, Nakashima H, Nakamura T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun. 2012;3:764.CrossRefPubMedPubMedCentral

26.

Androvitsanea A, Stylianou K, Maragkaki E, Tzanakakis M, Stratakis S, Petrakis I, Giatzakis C, Daphnis E. Vanishing urate, acute kidney injury episodes and a homozygous SLC2A9 mutation. Int Urol Nephrol. 2015;47(6):1035–6.CrossRefPubMed

27.

Stiburkova B, Ichida K, Sebesta I. Novel homozygous insertion in SLC2A9 gene caused renal hypouricemia. Mol Genet Metab. 2011;102(4):430–5.CrossRefPubMed

28.

Windpessl M, Ritelli M, Wallner M, Colombi M. A Novel Homozygous SLC2A9 Mutation Associated with Renal-Induced Hypouricemia. Am J Nephrol. 2016;43(4):245–50.CrossRefPubMed

29.

Gabrikova D, Bernasovska J, Sokolova J, Stiburkova B. High frequency of SLC22A12 variants causing renal hypouricemia 1 in the Czech and Slovak Roma population; simple and rapid detection method by allele-specific polymerase chain reaction. Urolithiasis. 2015;43(5):441–5.CrossRefPubMed

30.

Sulem P, Gudbjartsson DF, Walters GB, Helgadottir HT, Helgason A, Gudjonsson SA, Zanon C, Besenbacher S, Bjornsdottir G, Magnusson OT, et al. Identification of low-frequency variants associated with gout and serum uric acid levels. Nat Genet. 2011;43(11):1127–30.CrossRefPubMed

31.

Stiburkova B, Miyata H, Zavada J, Tomcik M, Pavelka K, Storkanova G, Toyoda Y, Takada T, Suzuki H. Novel dysfunctional variant in ABCG2 as a cause of severe tophaceous gout: biochemical, molecular genetics and functional analysis. Rheumatology (Oxford). 2016;55(1):191–4.CrossRef

32.

Li C, Li Z, Liu S, Wang C, Han L, Cui L, Zhou J, Zou H, Liu Z, Chen J, et al. Genome-wide association analysis identifies three new risk loci for gout arthritis in Han Chinese. Nat Commun. 2015;6:7041.CrossRefPubMedPubMedCentral

33.

Matsuo H, Yamamoto K, Nakaoka H, Nakayama A, Sakiyama M, Chiba T, Takahashi A, Nakamura T, Nakashima H, Takada Y, et al. Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. Ann Rheum Dis. 2016;75(4):652–9.CrossRefPubMed

34.

Nakayama A, Nakaoka H, Yamamoto K, Sakiyama M, Shaukat A, Toyoda Y, Okada Y, Kamatani Y, Nakamura T, Takada T, et al. GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. Ann Rheum Dis. 2017;76(5):869–77.CrossRefPubMed

35.

Qing YF, Zhou JG, Zhang QB, Wang DS, Li M, Yang QB, Huang CP, Yin L, Pan SY, Xie WG, et al. Association of TLR4 Gene rs2149356 polymorphism with primary gouty arthritis in a case-control study. PLoS One. 2013;8(5), e64845.CrossRefPubMedPubMedCentral

36.

Rasheed H, McKinney C, Stamp LK, Dalbeth N, Topless RK, Day R, Kannangara D, Williams K, Smith M, Janssen M, et al. The Toll-Like Receptor 4 (TLR4) Variant rs2149356 and Risk of Gout in European and Polynesian Sample Sets. PLoS One. 2016;11(1), e0147939.CrossRefPubMedPubMedCentral

37.

McKinney C, Stamp LK, Dalbeth N, Topless RK, Day RO, Kannangara DR, Williams KM, Janssen M, Jansen TL, Joosten LA, et al. Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout. Arthritis Res Ther. 2015;17:288.CrossRefPubMedPubMedCentral

38.

Cardona F, Tinahones FJ, Collantes E, Escudero A, Garcia-Fuentes E, Soriguer FJ. Contribution of polymorphisms in the apolipoprotein AI-CIII-AIV cluster to hyperlipidaemia in patients with gout. Ann Rheum Dis. 2005;64(1):85–8.CrossRefPubMed

39.

Rasheed H, Phipps-Green AJ, Topless R, Smith MD, Hill C, Lester S, Rischmueller M, Janssen M, Jansen TL, Joosten LA, et al. Replication of association of the apolipoprotein A1-C3-A4 gene cluster with the risk of gout. Rheumatology (Oxford). 2016;55(8):1421–30.CrossRef

40.

Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134–9.CrossRefPubMedPubMedCentral

41.

Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431–46.CrossRef

42.

Dalbeth N, Stamp L. Hyperuricaemia and gout: time for a new staging system? Ann Rheum Dis. 2014;73(9):1598–600.CrossRefPubMed

43.

Shiozawa A, Szabo SM, Bolzani A, Cheung A, Choi HK. Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review. J Rheumatol. 2017;44(3):388–96.CrossRefPubMed

44.

Merriman TR, Phipps-Green A, Boocock J, Riches P, Tausche A-K, Radstake T, Janssen M, Joosten LAB, Jansen TL, So A et al. Pleiotropic effect of ABCG2 in gout. In: American College of Rheumatology Annual Scientific Meeting. Washington DC, USA: Arthritis Rheumatol; 2016;68(suppl 10).

45.

Hollis-Moffatt JE, Gow PJ, Harrison AA, Highton J, Jones PB, Stamp LK, Dalbeth N, Merriman TR. The SLC2A9 nonsynonymous Arg265His variant and gout: evidence for a population-specific effect on severity. Arthritis Res Ther. 2011;13(3):R85.CrossRefPubMedPubMedCentral

46.

Tu HP, Ko AM, Chiang SL, Lee SS, Lai HM, Chung CM, Huang CM, Lee CH, Kuo TM, Hsieh MJ, et al. Joint effects of alcohol consumption and ABCG2 Q141K on chronic tophaceous gout risk. J Rheumatol. 2014;41(4):749–58.CrossRefPubMed

47.

He W, Phipps-Green A, Stamp LK, Merriman TR, Dalbeth N. Population-specific association between ABCG2 variants and tophaceous disease in people with gout. Arthritis Res Ther. 2017:in press.

48.

Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447–61.CrossRef

49.

Batt C, Phipps-Green AJ, Black MA, Cadzow M, Merriman ME, Topless R, Gow P, Harrison A, Highton J, Jones P, et al. Sugar-sweetened beverage consumption: a risk factor for prevalent gout with SLC2A9 genotype-specific effects on serum urate and risk of gout. Ann Rheum Dis. 2014;73(12):2101–6.CrossRefPubMed

50.

Hamajima N, Naito M, Okada R, Kawai S, Yin G, Morita E, Higashibata T, Tamura T, Nakagawa H, Matsuo H. Significant interaction between LRP2 rs2544390 in intron 1 and alcohol drinking for serum uric acid levels among a Japanese population. Gene. 2012;503(1):131–6.CrossRefPubMed

51.

Rasheed H, Phipps-Green A, Topless R, Hollis-Moffatt JE, Hindmarsh JH, Franklin C, Dalbeth N, Jones PB, White DH, Stamp LK. Association of the lipoprotein receptor-related protein 2 gene with gout and non-additive interaction with alcohol consumption. Arthritis Res Ther. 2013;15(6):R177.CrossRefPubMedPubMedCentral

52.

Tu HP, Chung CM, Min-Shan Ko A, Lee SS, Lai HM, Lee CH, Huang CM, Liu CS, Ko YC. Additive composite ABCG2, SLC2A9 and SLC22A12 scores of high-risk alleles with alcohol use modulate gout risk. J Hum Genet. 2016;61(9):803–10.CrossRefPubMed

53.

Wen C, Yee S, Liang X, Hoffmann T, Kvall M, Banda Y, Jorgenson E, Schaefer C, Risch N, Giacomini K. Genome-wide association study identifies ABCG2 (BRCP) as an allopurinol transporter and a determinant of drug response. Clin Pharm Ther. 2015;97(5):518–25.CrossRef

54.

Roberts RL, Wallace MC, Phipps-Green AJ, Topless R, Drake JM, Tan P, Dalbeth N, Merriman TR, Stamp LK: ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenomics J. 2016, doi: 10.1038/tpj.2015.101.

55.

Hartmann T, Terao M, Garattini E, Teutloff C, Alfaro J, Jones J, Leimkuhler S. The impact of single nucleotide polymorphisms on human aldehyde oxidase. Drug Metab Dispos. 2012;40(5):856–64.CrossRefPubMedPubMedCentral

56.

Roberts R, Zhang M, Marinaki A, Stamp L. Does genetic variability in aldehyde oxidoreductase and molybdenum cofactor sulfurase predict non-response to allopurinol? Aliment Pharmacol Ther. 2010;32:310–1.CrossRefPubMed

57.

Carroll M, Smith D, Shaak T. Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose. Rheumatol Int. 2016;37(3):445–53. doi:10.1007/s00296-016-3592-2.CrossRefPubMed

58.

Miyata H, Takeda T, Toyoda Y, Matsuo H, Ichida K, Suzuki H. Identification of febuxostat as a new strong ABCG2 inhibitor: potential applications and risks in clinical situations. Front Pharmacol. 2016, doi: 10.3389/pharf.2016.00518.

59.

Shin H, Takeda M, Enomoto A, Fujimura M, Miyazaki H, Anzai N, Endou H. Interactions of urate transporter URAT1 in human kidney with uricosuric drugs. Nephrology (Carlton). 2011;16(2):156–62.CrossRef

60.

Miner J, Tan P, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty D, Manhard K, Shen Z, Girardet J-L, et al. Lerinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibiton of urate transporters in the kidney. Arthritis Res Ther. 2016;18(1):214.. doi:10.1186/s13075-016-1107-x.CrossRefPubMedPubMedCentral

61.

Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Endou H, Hosoya T. Clinical and Molecular Analysis of Patients with Renal Hypouricemia in Japan-Influence of URAT1 Gene on Urinary Urate Excretion. J Am Soc Nephrol. 2004;15:164–73.CrossRefPubMed

62.

Ko TM, Tsai CY, Chen SY, Chen KS, Yu KH, Chu CS, Huang CM, Wang CR, Weng CT, Yu CL, et al. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ. 2015;351:h4848.CrossRefPubMedPubMedCentral

63.

Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18(2):99–107.CrossRefPubMed

64.

Genin E, Schumacher M, Roujeau JC, Naldi L, Liss Y, Kazma R, Sekula P, Hovnanian A, Mockenhaupt M. Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. Orphanet J Rare Dis. 2011;6:52.CrossRefPubMedPubMedCentral

65.

Roberts RL, Wallace MC, Harrison A, Dalbeth N, Merriman TR, Stamp LK. A human leukocyte antigen locus haplotype confers risk for allopurinol-related adverse effects in Caucasian patients with gout. Pharmacogenet Genomics. 2015;25(8):412–5.CrossRefPubMed

66.

Uchida S, Shimada K, Misaka S, Imai H, Katoh Y, Inui N, Takeuchi K, Ishizaki T, Yamada S, Ohashi K, et al. Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes. Drug Metab Pharmacokinet. 2010;25(6):605–10.CrossRefPubMed

67.

Roberts RL, Wallace MC, Wright DF, Cadzow M, Dalbeth N, Jones PB, Stamp LK, Harrison AA, Black MA, Merriman TR. Frequency of CYP2C9 polymorphisms in Polynesian people and potential relevance to management of gout with benzbromarone. Joint Bone Spine. 2014;81(2):160–3.CrossRefPubMed

68.

Pilotto A, Seripa D, Franceschi M, Scarcelli C, Colaizzo D, Grandone E, Niro V, Andriulli A, Leandro G, Di Mario F, et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology. 2007;133(2):465–71.CrossRefPubMed

69.

Jackson G, Dalbeth N, Te Karu L, Winnard D, Gow P, Gerard C, Minko N. Variation in gout care in Aotearoa New Zealand: a national analysis of quality markers. N Z Med J. 2014;127(1404):37–47.PubMed

70.

Singh JA, Bharat A, Khanna D, Aquino-Beaton C, Persselin JE, Duffy E, Elashoff D, Khanna PP. Racial differences in health-related quality of life and functional ability in patients with gout. Rheumatology (Oxford). 2017;56(1):103–12.CrossRef

71.

Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annu Rev Physiol. 2015;77:323–45.CrossRefPubMed

72.

Miner J, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet JL, et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016;18(1):214.CrossRefPubMedPubMedCentral

73.

Hagos Y, Stein D, Ugele B, Burckhardt G, Bahn A. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol. 2007;18(2):430–9.CrossRefPubMed

74.

Caulfield MJ, Munroe PB, O'Neill D, Witkowska K, Charchar FJ, Doblado M, Evans S, Eyheramendy S, Onipinla A, Howard P, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med. 2008;5(10), e197.CrossRefPubMedPubMedCentral

75.

Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447–52.PubMed

76.

van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2002;13(3):595–603.PubMed

77.

Sweet DH, Chan LM, Walden R, Yang XP, Miller DS, Pritchard JB. Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na + gradient. Am J Physiol Renal Physiol. 2003;284(4):F763–769.CrossRefPubMed

78.

Enomoto A, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, Kobayashi Y, Yamamoto T, Sekine T, Cha SH, Niwa T, et al. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther. 2002;301(3):797–802.CrossRefPubMed

79.

Aslamkhan A, Han YH, Walden R, Sweet DH, Pritchard JB. Stoichiometry of organic anion/dicarboxylate exchange in membrane vesicles from rat renal cortex and hOAT1-expressing cells. Am J Physiol Renal Physiol. 2003;285(4):F775–783.CrossRefPubMed

80.

Jutabha P, Kanai Y, Hosoyamada M, Chairoungdua A, Kim DK, Iribe Y, Babu E, Kim JY, Anzai N, Chatsudthipong V, et al. Identification of a novel voltage-driven organic anion transporter present at apical membrane of renal proximal tubule. J Biol Chem. 2003;278(30):27930–8.CrossRefPubMed

81.

Dalbeth N, Merriman T. Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout. Rheumatology (Oxford). 2009;48(3):222–6.CrossRef

Title: The genetics of gout: towards personalised medicine?
Authors: Nicola Dalbeth
Lisa K. Stamp
Tony R. Merriman
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Medicine / Issue 1/2017
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/s12916-017-0878-5

At a glance: The STEP trials

Springer Medicine

The genetics of gout: towards personalised medicine?

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

The effect of an antenatal lifestyle intervention in overweight and obese women on circulating cardiometabolic and inflammatory biomarkers: secondary analyses from the LIMIT randomised trial

Closed-loop for type 1 diabetes – an introduction and appraisal for the generalist

Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new

What makes gouty inflammation so variable?

Can incontinence be cured? A systematic review of cure rates

What is the association of hypothyroidism with risks of cardiovascular events and mortality? A meta-analysis of 55 cohort studies involving 1,898,314 participants